IVU Traffic Technologies AG

  • WKN: 744850
  • ISIN: DE0007448508
  • Land: Deutschland

Nachricht vom 20.09.2021 | 11:00

IVU Traffic Technologies AG: Release of a capital market information

IVU Traffic Technologies AG / Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of Regulation (EU) No. 596/2014 - 1st Interim Announcement
20.09.2021 / 11:00
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

IVU Traffic Technologies AG

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of Regulation (EU) No. 596/2014 - 1st Interim Announcement

In the period from 14 September 2021 up to and including 17 September 2021, IVU Traffic Technologies AG acquired a total of 14,107 shares in the company at a volume-weighted average price of EUR 19.7798 as part of its current share buyback programme, which was announced with the announcement of 14 September 2021 in accordance with Art. 5 Sec. 1 letter a) of Regulation (EU) No. 596/2014 and Art. 2 Sec. 1 of Delegate Regulation (EU) No. 2016/1052.

The number of the shares bought back are as follows

Date Total volume of repurchased shares (units) Volume-weighted average price (EUR)1
14 September 2021 1,613 19.6810
15 September 2021 4,200 19.9200
16 September 2021 3,994 19.7245
17 September 2021 4,300 19.7937
Total 14,107 19.7798
 

1 Excluding incidental purchasing costs, rounded to four places according to commercial practice.

The total number of shares bought back by IVU Traffic Technologies AG since 14 September 2021 within the share buyback programme amounts to 14,107 shares. The acquisition of the shares of IVU Traffic Technologies AG is carried out on the basis of the ad-hoc announcement of 14 September 2021 by a bank commissioned by the company exclusively via the stock exchange (XETRA trading).

Detailed information is available on the Company's website www.ivu.com under Investor Relations/IVU Share.

Berlin, 20 September 2021
The Executive Board



20.09.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021